Main Article Content
This review article summarizes the existing literature on the current state of the problem of diabetes mellitus and acute coronary syndromes. In particular, the issues are analyzed related to the etiology, epidemiology, main pathophysiological features, classification of acute coronary syndromes, acute coronary syndromes without persistent ST-segment elevation on the electrocardiogram, acute coronary syndromes with ST-segment elevation, non-atherosclerotic causes of acute coronary syndrome, laboratory and instrumental diagnostic tests. Issues were analyzed related to the main approaches to the treatment of acute coronary syndromes, management of patients with diabetes mellitus and acute coronary syndromes, recommendations for secondary prevention. Initial treatment with corticosteroids includes acetylsalicylic acid, bolus heparin and intravenous heparin infusion (in the absence of contraindications). Antiplatelet therapy with ticagrelor or clopidogrel is also recommended. Pain is controlled using morphine/fentanyl and oxygen in case of hypoxia. Nitroglycerin can also be used sublingually or by infusion to relieve pain. Continuous monitoring of myocardial activity for arrhythmia is required. The choice of reperfusion strategy in patients with diabetes mellitus should be based on many factors, including assessment of clinical status (hemodynamic/electrical instability, prolonged ischemia), complications of chronic coronary syndrome, ischemic load, echocardiography, assessment of left ventricular function and any other comorbidities. In addition, various methods for assessing coronary artery disease and predicting mortality due to surgery are needed to make a final decision. Advances in the sensitivity of cardiac biomarkers and the use of risk assessment tools now enable rapid diagnosis within a few hours of symptom onset. Advances in the invasive management and drug therapy have resulted in improved clinical outcomes with resultant decline in mortality associated with acute coronary syndrome.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575.
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi:10.2991/jegh.k.191028.001.
Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Recent advances in the treatment of neuropathies in type 2 diabetes mellitus patients: Focus on benfotiamine (review and own data). In: Berhardt LV, editor. Advances in Medicine and Biology (Numbered Series). Vol 166. New York: Nova Science Publishers; 2020. 1-80 pp.
Tillin T, Hughes AD, Mayet J, et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) -- a prospective population-based study. J Am Coll Cardiol. 2013 Apr 30;61(17):1777-1786. doi:10.1016/j.jacc.2012.12.046.
Arnold SV, Lipska KJ, Li Y, et al. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J. 2014 Oct;168(4):466-470.e1. doi:10.1016/j.ahj.2014.06.023.
O'Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10;60(2):106-11. doi:10.1016/j.jacc.2012.02.059.
Planer D, Witzenbichler B, Guagliumi G, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol. 2013 Sep 10;167(6):2572-2579. doi:10.1016/j.ijcard.2012.06.054.
Ekmekci A, Cicek G, Uluganyan M, et al. Admission hyperglycemia predicts inhospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus. Angiology. 2014 Feb;65(2):154-159. doi:10.1177/0003319713488930.
Lettino M, Andell P, Zeymer U, et al. Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):198-213. doi:10.1093/ehjcvp/pvw049.
Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun;165(6):918-925.e2. doi:10.1016/j.ahj.2013.01.005.
Gustafsson I, Hvelplund A, Hansen KW, et al. Underuse of an invasive strategy for patients with diabetes with acute coronary syndrome: a nationwide study. Open Heart. 2015 Feb 6;2(1):e000165. doi:10.1136/openhrt-2014-000165.
Tardif JC, L'Allier PL, Fitchett DH; Diabetes Canada Clinical Practice Guidelines Expert Committee. Management of Acute Coronary Syndromes. Can J Diabetes. 2018 Apr;42(Suppl 1):S190-S195. doi:10.1016/j.jcjd.2017.10.029.
Nikitina EA. Impact of type 2 diabetes mellitus on clinical and functional features and prognosis in patients with acute coronary syndrome. Eruditio Juvenium. 2019;7(1):11-18. doi:10.23888/HMJ20197111-18. (in Russian).
Ruda MYa, Averkov OV, Panchenko EP, Iavelov IS. Diagnostika i lechenie bol'nykh c ostrym koronarnym sindromom bez pod"ema segmenta ST elektrokardiogrammy: Rekomendatsii Obshchestva spetsialistov po neotlozhnoi kardiologii [Diagnosis and treatment of patients with acute coronary syndrome without ST-segment elevation electrocardiogram: Society of Emergency Cardiology Recommendations]. Moscow; 2015. 95 p. (in Russian).
Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for acute ST-segment elevation myocardial infarction. Russ J Cardiol. 2020;25(11):4103. doi:10.15829/1560-4071-2020-4103. (in Russian).
Zègre-Hemsey JK, Asafu-Adjei J, Fernandez A, Brice J. Characteristics of Prehospital Electrocardiogram Use in North Carolina Using a Novel Linkage of Emergency Medical Services and Emergency Department Data. Prehosp Emerg Care. 2019 Nov-Dec;23(6):772-779. doi:10.1080/10903127.2019.1597230.
Alomari M, Bratton H, Musmar A, Al Momani LA, Young M. Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention. Cureus. 2019 Jan 12;11(1):e3874. doi:10.7759/cureus.3874.
Voudris KV, Kavinsky CJ. Advances in Management of Stable Coronary Artery Disease: the Role of Revascularization? Curr Treat Options Cardiovasc Med. 2019 Mar 11;21(3):15. doi:10.1007/s11936-019-0720-9.
Severino P, D'Amato A, Pucci M, et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int J Mol Sci. 2020 Oct 30;21(21):8118. doi:10.3390/ijms21218118.
Sweis RN, Jivan A. Overview of acute coronary syndromes (ACS) (Unstable Angina; Acute MI; Myocardial Infarction). Available from: https://www.msdmanuals.com/professional/cardiovascular-disorders/coronary-artery-disease/overview-of-acute-coronary-syndromes-acs. Accessed: July 2020.
Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russ J Cardiol. 2021;26(4):4449. doi:10.15829/1560-4071-2021-4449. (in Russian).
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi:10.1093/eurheartj/eht296.
Lee JW, Moon JS, Kang DR, et al. Clinical Impact of Atypical Chest Pain and Diabetes Mellitus in Patients with Acute Myocardial Infarction from Prospective KAMIR-NIH Registry. J Clin Med. 2020 Feb 12;9(2):505. doi:10.3390/jcm9020505.
Luciano LSC, Silva RLD, Londero Filho OM, et al. Analysis of the Appropriate Use Criteria for Coronary Angiography in Two Cardiology Services of Southern Brazil. Arq Bras Cardiol. 2019 May;112(5):526-531. doi:10.5935/abc.20190055.
Campanile A, Castellani C, Santucci A, et al. Predictors of in-hospital and long-term mortality in unselected patients admitted to a modern coronary care unit. J Cardiovasc Med (Hagerstown). 2019 May;20(5):327-334. doi:10.2459/JCM.0000000000000785.
Chen WWC, Law KK, Li SK, et al. Extended dual antiplatelet therapy for Asian patients with acute coronary syndrome: expert recommendations. Intern Med J. 2019 Mar;49 Suppl 1:5-8. doi:10.1111/imj.14153.
Gao X, Zeng R, Liao P, Zhu H, Zhang M. Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2016 Oct;76(6):460-464. doi:10.1080/00365513.2016.1199048.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi:10.1093/eurheartj/ehx393.
Ahn KT, Seong SW, Choi UL, et al. Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention. Medicine (Baltimore). 2019 Mar;98(11):e14833. doi:10.1097/MD.0000000000014833.
Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi:10.1161/ATVBAHA.118.311963.
Koval SM, Yushko KO, Snihurska IO, et al. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertension (Poland) 2019;23(3):183-189. doi:10.5603/AH.a2019.0012.
Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013 May;43(5):1006-1013. doi:10.1093/ejcts/ezt017.
Bonin M, Mewton N, Roubille F, et al. Effect and Safety of Morphine Use in Acute Anterior ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc. 2018 Feb 10;7(4):e006833. doi:10.1161/JAHA.117.006833.
Shah R, Rashid A, Hwang I, Fan TM, Khouzam RN, Reed GL. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. Am J Cardiol. 2017 Jun 1;119(11):1723-1728. doi:10.1016/j.amjcard.2017.03.011.
Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 7;37(14):1133-1142. doi:10.1093/eurheartj/ehv531.
Schjerning Olsen AM, Lindhardsen J, Gislason GH, et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ. 2015 Oct 19;351:h5096. doi:10.1136/bmj.h5096.
Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019 Jun 21;40(24):1963-1970. doi:10.1093/eurheartj/ehz104.
James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010 Dec;31(24):3006-3016. doi:10.1093/eurheartj/ehq325.
Ruda MYa, Averkov OV, Panchenko EP, Iavelov IS. Guideline for the management of patients with non-ST-elevation acute coronary syndromes (part 2). Russ Cardiol Bull. 2018;13(1):58-62. doi:10.17116/Cardiobulletin201813159-62. (in Russian).
Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283-293. doi:10.1016/S0140-6736(09)62191-7.
Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14;67(23):2732-2740. doi:10.1016/j.jacc.2016.03.529.
Abdur Rehman K, Wazni OM, Barakat AF, et al. Life-Threatening Complications of Atrial Fibrillation Ablation: 16-Year Experience in a Large Prospective Tertiary Care Cohort. JACC Clin Electrophysiol. 2019 Mar;5(3):284-291. doi:10.1016/j.jacep.2018.11.013.
Xia K, Wang LF, Yang XC, et al. Comparing the effects of depression, anxiety, and comorbidity on quality-of-life, adverse outcomes, and medical expenditure in Chinese patients with acute coronary syndrome. Chin Med J (Engl). 2019 May 5;132(9):1045-1052. doi:10.1097/CM9.0000000000000215.